Homeo House (India) P Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 30 Year, 8 Months
- Last Filing with ROC 31 Mar 2020
- Revenue Growth 5.70%
- Profit Growth -7.54%
- Ebitda 2.08%
- Net Worth 6.30%
- Total Assets 6.51%
About Homeo House (India) P
Homeo House (India) P Ltd (HHIPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 June 1994 and has a history of 30 years and eight months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Hufriz Basta and Pharaoh Basta serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230MH1994PTC079046
-
Company No.
079046
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
17 Jun 1994
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Homeo House (India) P?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Hufriz Basta
|
Director | 17-Jun-1994 | Current |
|
Pharaoh Basta
|
Director | 17-Jun-1994 | Current |
Financial Performance of Homeo House (India) P.
Homeo House (India) P Ltd, for the financial year ended 2020, experienced modest growth in revenue, with a 5.7% increase. The company also saw a slight decrease in profitability, with a 7.54% decrease in profit. The company's net worth moved up by a moderate rise of 6.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Homeo House (India) P?
In 2017, Homeo House (India) P had a promoter holding of 40.00% and a public holding of 60.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Andheri Pharmaceuticals Pvt LtdHufriz Basta and Pharaoh Basta are mutual person
-
Ghatkopar Homeopathic Pharmacy P Ltd
Hufriz Basta and Pharaoh Basta are mutual person
-
Fort Homeo Pharmacy Private Limited
Hufriz Basta and Pharaoh Basta are mutual person
-
Byculla Homeopathic Pharmacy P Ltd
Hufriz Basta and Pharaoh Basta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Homeo House (India) P?
Unlock and access historical data on people associated with Homeo House (India) P, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Homeo House (India) P, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Homeo House (India) P's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.